ORPHA:67043
Amoebic keratitis
Publications
602
85.9th percentile
Trials
6
Interventional, condition-specific
Researchers
1,060
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare corneal infection due to the protozoan Acanthamoeba that generally occurs in contact lens wearers and that is characterized by severe ocular pain, blepharospasm, photophobia, eye tearing, blurred vision and foreign body sensation. It can lead to impaired visual acuity if not treated promptly.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005629
- MeSH:D015823
- UMLS:C0000880
- NCIT:C50450
Additional Mondo synonyms (2)
Acanthamoeba caused keratitis · keratitis, Acanthamoeba
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
602 matched papers (328 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
6 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
602
602 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
602 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
328 in the last 10 years · high confidence · 85.9th percentile (publications denominator)
Phrase hits: 548 · MeSH hits: 59
Who's working on it?
1,060
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Lorenzo-Morales J15 papers · 2026
University Institute of Tropical Diseases and Public Health, University of La Laguna, Avda Francisco Sanchez s/n, Campus de Anchieta, 38271 la Laguna, Tenerife, Canary Islands, Spain.
Papers in Europe PMC - 02Piñero JE12 papers · 2026
University Institute of Tropical Diseases and Public Health, University of La Laguna, Avda Francisco Sanchez s/n, Campus de Anchieta, 38271 la Laguna, Tenerife, Canary Islands, Spain.
Papers in Europe PMC - 03Niyyati M8 papers · 2026
Dept. of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Papers in Europe PMC - 04Reyes-Batlle M8 papers · 2026
University Institute of Tropical Diseases and Public Health, University of La Laguna, Avda Francisco Sanchez S/n, Campus de Anchieta, 38271 La Laguna, Tenerife, Canary Islands, Spain.
Papers in Europe PMC - 05Pérez-Pérez P7 papers · 2026
Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna (ULL), 38200 San Cristóbal de La Laguna, Spain.
Papers in Europe PMC - 06Sifaoui I7 papers · 2026
Laboratoire Matériaux-Molécules et Applications, IPEST, B.P. 51, 2070 La Marsa, University of Carthage, Tunisia; University Institute of Tropical Diseases and Public Health, University of La Laguna, Avda Francisco Sanchez s/n, Campus de Anchieta, 38271 la Laguna, Tenerife, Canary Islands, Spain.
Papers in Europe PMC - 07Soleimani M6 papers · 2026
Ocular Trauma and Emergency Department, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Papers in Europe PMC - 08Latifi A5 papers · 2025
Dept. of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Papers in Europe PMC - 09Nissapatorn V5 papers · 2026
Department of Parasitology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia; School of Allied Health Sciences, Walailak University, 80161 Nakhon Si Thammarat, Thailand. Electronic address: nissapat@gmail.com.
Papers in Europe PMC - 10Omaña-Molina M5 papers · 2024
School of Superior Studies Iztacala, UNAM, Los Reyes Iztacala, Tlalnepantla, Mexico State, Mexico. maritzaomanam@yahoo.com.mx.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
6
interventional trials for this specific condition
6 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 107 trials are registered for keratitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
6 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 89th percentile).
high confidence · 89th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
6 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06213649·RECRUITING·Parasitic Ulcer Treatment Trial
Conditions: Acanthamoeba Keratitis·Matched via MeSH
Broader category: keratitis
107
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06975748·RECRUITING·A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis
Conditions: Neurotrophic Keratitis·Matched via name phrase
- NCT07308938·NOT YET RECRUITING·Fluorometholone Study
Conditions: Keratitis Bacterial · Corneal Ulcer (Diagnosis)·Matched via name phrase
- NCT07329686·RECRUITING·Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.
Conditions: Herpes Simplex Keratitis · Corneal Neovascularization·Matched via name phrase
- NCT06964269·RECRUITING·Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
Conditions: Autoimmune Diseases · Dry Eye · Neurotrophic Keratitis·Matched via name phrase
- NCT07568730·RECRUITING·A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
Conditions: Neurotrophic Keratitis·Matched via name phrase
- NCT06658002·RECRUITING·Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
Conditions: Fungal Keratitis · Corneal Ulcer·Matched via name phrase
- NCT06451172·RECRUITING·Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
Conditions: Bacterial Keratitis · Antibiotic-resistant Bacteria · Infections, Bacterial · Corneal Diseases·Matched via name phrase
- NCT07452588·NOT YET RECRUITING·Effect of Sodium Chloride 5% Solution as an Adjuvant Treatment With Antimicrobial Therapy in the Treatment of Bacterial Infectious Keratitis
Conditions: Infectious Keratitis · Adjuvant Treatment Bacterial Infectious Keratitis · Sodium Chloride 5% Solution·Matched via name phrase
- NCT06463678·NOT YET RECRUITING·Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis
Conditions: Fungal Keratitis·Matched via name phrase
- NCT06999733·RECRUITING·A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
Conditions: Neurotrophic Keratitis·Matched via name phrase
- NCT07073729·NOT YET RECRUITING·Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot Study
Conditions: Neurotrophic Keratitis·Matched via name phrase
- NCT05927428·RECRUITING·Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
Conditions: Neurotrophic Keratitis·Matched via name phrase
- NCT06474442·RECRUITING·A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis
Conditions: Herpes Simplex Virus Type I Stromal Keratitis·Matched via name phrase
- NCT07394257·RECRUITING·Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis
Conditions: Bacterial Keratitis · Recalcitrant Infectious Keratitis · Corneal Ulcer·Matched via name phrase
- NCT03918408·RECRUITING·Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking
Conditions: Keratoconus, Unstable · Bacterial Keratitis · Ectasia of Cornea·Matched via name phrase
Observational and natural-history studies
4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Amoebic keratitis" OR "Acanthamoeba caused keratitis" OR "keratitis, Acanthamoeba"
MeSH descriptor terms unioned into the query: Acanthamoeba Keratitis
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Amoebic keratitis" OR "Acanthamoeba caused keratitis" OR "keratitis, Acanthamoeba" OR "Acanthamoeba Keratitis"
Interventional trials matched via: mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 6 interventional · 4 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"keratitis"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T01:25:45.740Z
